Omeros Corp (OMER)
NASDAQ:OMER
Want to see OMER full AI Analyst Report?
OMER Stock Chart & Stats
$13.44
-$0.23(-2.31%)
At close: 4:00 PM EST
$13.44
-$0.23(-2.31%)
Day’s Range― - ―
52-Week Range$2.95 - $17.65
Previous CloseN/A
Volume193.12K
Average Volume (3M)1.09M
Market Cap
$1.08B
Enterprise Value$1.31B
Total Cash (Recent Filing)$171.80M
Total Debt (Recent Filing)$239.14M
Price to Earnings (P/E)3.2
Beta1.08
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.98
Shares Outstanding71,996,170
10 Day Avg. Volume1,148,813
30 Day Avg. Volume1,091,687
Financial Highlights & Ratios
PEG Ratio3.32
Price to Book (P/B)-9.00
Price to Sales (P/S)0.00
P/FCF Ratio-9.39
Enterprise Value/Market Cap1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-127.63
Enterprise Value/Ebitda-11.92
Forecast
1Y Price Target
$40.00Price Target Upside197.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.33
Revenue Forecast (FY)$132.05M
Bulls Say, Bears Say
Bulls Say
Cash Flow OutlookManagement expects the Yartemlea business to become self-sustaining and generate positive cash flow within the company’s forecast horizon, enabling reinvestment into the pipeline and potential partnerships.
Pipeline AdvancementOncotoX-AML preclinical results showed selective reduction of malignant myeloid cells while preserving stem cells and delivered stronger tumor control in animal studies, supporting advancement toward human trials.
Product Launch MomentumRapid engagement with transplant centers, early formulary wins, and minimal reimbursement friction are translating into utilization for Yartemlea and support upside to near-term revenue expectations.
Bears Say
Disclosure And VisibilityThe company disclosed limited quantitative details about the Yartemlea launch, creating uncertainty around commercial performance and making revenue forecasting more difficult for analysts.
Earnings QualityA profit beat driven by recognition of an upfront licensing payment for OMS906 may represent a one-time accounting benefit, introducing risk of earnings volatility and potential overstatement of operational results.
Valuation RiskAnalyst Hold cites that the current valuation already reflects significant expected Yartemlea sales, which could limit upside for the stock if launch outcomes only meet expectations.
Omeros News
OMER FAQ
What was Omeros Corp’s price range in the past 12 months?
Omeros Corp lowest stock price was $2.95 and its highest was $17.65 in the past 12 months.
What is Omeros Corp’s market cap?
Omeros Corp’s market cap is $1.08B.
When is Omeros Corp’s upcoming earnings report date?
Omeros Corp’s upcoming earnings report date is May 20, 2026 which is in 16 days.
How were Omeros Corp’s earnings last quarter?
Omeros Corp released its earnings results on Mar 31, 2026. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of -$0.301 by $1.281.
Is Omeros Corp overvalued?
According to Wall Street analysts Omeros Corp’s price is currently Undervalued.
Does Omeros Corp pay dividends?
Omeros Corp does not currently pay dividends.
What is Omeros Corp’s EPS estimate?
Omeros Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Omeros Corp have?
Omeros Corp has 71,996,170 shares outstanding.
What happened to Omeros Corp’s price movement after its last earnings report?
Omeros Corp reported an EPS of $0.98 in its last earnings report, beating expectations of -$0.301. Following the earnings report the stock price went up 14.394%.
Which hedge fund is a major shareholder of Omeros Corp?
Currently, no hedge funds are holding shares in OMER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.00 (197.62% Upside)
$40.00 (197.62% Upside)
Blogger Sentiment
Neutral
OMER Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.3%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.23%
12-Months-Change
Fundamentals
Return on Equity
1.71%
Trailing 12-Months
Asset Growth
17.52%
Trailing 12-Months
Company Description
Omeros Corp
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
OMER Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum driven by two transformative events: the zaltenibart transaction with Novo Nordisk (large upfront payment, milestones and royalties) and FDA approval plus early commercial traction for YARTEMLEA. Financially, Q4 showed a swing to GAAP net income and robust non-GAAP profitability, materially improved cash position and eliminated several near-term debt obligations. Early launch metrics (payer approvals, rapid delivery, per-vial pricing and initial formulary wins) and pipeline progress add to the constructive outlook. Key risks include noncash volatility from embedded derivative mark-to-market adjustments, remaining 2029 convertible note exposure, incomplete formulary penetration (still early), and a regulatory request delaying one external program. Overall, highlights outweigh the lowlights, with commercialization execution and the Novo transaction materially de-risking the company’s near-term prospects.View all OMER earnings summariesOMER Stock 12 Month Forecast
Average Price Target
$40.00
▲(197.62% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Abeona Therapeutics
―
―
Foghorn Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.75% Insiders
8.01% Mutual Funds
0.60% Other Institutional Investors
76.72% Public Companies and Individual Investors